Biomarkers for Carcinoid Heart Disease

#1586

Introduction: Carcinoid heart disease (CHD) develops in patients with carcinoid syndrome. Currently NT-proBNP (NTP) is suggested as the best current biomarker to screen for CHD and monitor heart failure. A number of other markers have been investigated for heart failure.

Aim(s): In this study we have assessed these markers in three cohorts of NET patients to determine how they compared with NTP.

Materials and methods: 3 groups of sbNET patients (n=37) were identified: CHD (Group A, n=10), non-functional (Groups B, n=12, normal CgA, 5HIAA, BNP), functional (Group C, n=15, elevated chromogranin A (CgA) & urine 5HIAA, normal BNP). Analysis was performed using NTP, GAL3, ST2, calprotectin and adrenomedullin assays. Statistical analysis was performed with SPSS.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Srirajaskanthan R

Authors: Basuroy R, Srirajaskanthan R, Ramage J, Sherwood R,

Keywords: carcinoid heart disease,